Unknown PHASE2 INTERVENTIONAL NCT00689702

Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer (XERT)

Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Locally Advanced Resectable Rectal Cancer: A Phase II Pilot Study

Sponsor: Institute of Oncology Ljubljana

Conditions Rectal Cancer

Interventions cetuximab, capecitabine

Updated 5 times since 2017 Last updated: Mar 23, 2012 Started: Feb 28, 2007 Primary completion: Apr 30, 2009 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00689702, this PHASE2 trial focuses on Rectal Cancer and remains ongoing. Sponsored by Institute of Oncology Ljubljana, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute of Oncology Ljubljana

Data source: Institute of Oncology Ljubljana

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ljubljana, Slovenia